In Vivo Inhibition of Dipeptidyl Peptidase 4 Allows Measurement of GLP-1 Secretion in Mice
Diabetes · 2024
DOI: 10.2337/db23-0848 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2024. Verfasst von Mark M Smits und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors, Aminobutyrates, Biphenyl Compounds. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, ERC, Novo Nordisk Foundation.
Abstract (Originalsprache)
Dipeptidyl peptidase 4 (DPP-4) and neprilysin (NEP) rapidly degrade glucagon-like peptide 1 (GLP-1) in mice. Commercially available sandwich ELISA kits may not accurately detect the degradation products, leading to potentially misleading results. We aimed to stabilize GLP-1 in mice, allowing reliable measurement with sensitive commercially available ELISA kits. Nonanesthetized male C57Bl/6JRj mice were subjected to an oral glucose tolerance test (OGTT; 2 g/kg glucose), and plasma total and intact GLP-1 were measured (Mercodia and Alpco ELISA kits, respectively). No GLP-1 increases were seen in samples taken beyond 15 min after the glucose load. Samples taken at 5 and 10 min after the OGTT showed a minor increase in total, but not intact, GLP-1. We then administered saline (control), or a DPP-4 inhibitor (valine pyrrolidide or sitagliptin) with or without an NEP-inhibitor (sacubitril), 30 min before the OGTT. In the inhibitor groups only, intact GLP-1 increased significantly during the OGTT. After injecting male C57Bl/6JRj mice with a known dose of GLP-1(7-36)NH2, peak GLP-1 levels were barely detectable after saline but were 5- to 10-fold higher during sitagliptin and the combination of sitagliptin/sacubitril. The half-life of the GLP-1 plasma disappearance increased up to sevenfold during inhibitor treatment. We conclude that reliable measurement of GLP-1 secretion is not possible in mice in vivo with commercially available sandwich ELISA kits, unless degradation is prevented by inhibition of DPP-4 and perhaps NEP. The described approach allows improved estimates of GLP-1 secretion for future studies, although it is a limitation that these inhibitors additionally influence levels of insulin and glucagon. Article Highlights
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Clinical Biochemistry, University Hospital Copenhagen-Bispebjerg, Copenhagen, Denmark.
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Mark M Smits, Katrine D Galsgaard, Sara Lind Jepsen, Nicolai Wewer Albrechtsen, Bolette Hartmann, Jens J Holst
Förderung
- Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers
- ERC
- Novo Nordisk Foundation
- Lundbeck postdoc fellowship
Zitieren
APA
Smits, M. M., Galsgaard, K. D., Jepsen, S. L., Albrechtsen, N. W., Hartmann, B., & Holst, J. J. (2024). In Vivo Inhibition of Dipeptidyl Peptidase 4 Allows Measurement of GLP-1 Secretion in Mice. Diabetes. https://doi.org/10.2337/db23-0848
Vancouver
Smits MM, Galsgaard KD, Jepsen SL, Albrechtsen NW, Hartmann B, Holst JJ. In Vivo Inhibition of Dipeptidyl Peptidase 4 Allows Measurement of GLP-1 Secretion in Mice. Diabetes. 2024. doi:10.2337/db23-0848
BibTeX
@article{Smits2024,
author = {Smits, Mark M and Galsgaard, Katrine D and Jepsen, Sara Lind and Albrechtsen, Nicolai Wewer and Hartmann, Bolette and Holst, Jens J},
title = {In Vivo Inhibition of Dipeptidyl Peptidase 4 Allows Measurement of GLP-1 Secretion in Mice},
journal = {Diabetes},
year = {2024},
doi = {10.2337/db23-0848}
}
EUVIMED